ClinicalTrials.gg
Active, not recruitingNCT06564311Updated Nov 17, 2025

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

A Phase 2 interventional study of Obexelimab and Placebo in Relapsing Multiple Sclerosis, sponsored by Zenas BioPharma (USA), LLC. Active, not recruiting at 47 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Zenas BioPharma (USA), LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
290th of 879
93 · median 50
Started
2024
with 56 others
Phase 2
139 of 1,192
20 open now
Primary completion
2025-08
later than 24 of 256 live
Registered
1,079th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 290th largest by planned enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2024, is one of 139 in phase 2, reaches primary completion later than 24 of the 256 other live ones, and was the 1,079th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

Read the detailed description

The study consists of a Screening Period (Day -28 to Day -1), a 24-week treatment period (Part A and Part B), a 52 week open label extension and an expected 12-week Follow-up Period. Patients with Relapsing Multiple Sclerosis will be randomized in 2:1 ratio to obexelimab or placebo. Randomization will be stratified by Gd lesion status at screening (≥ 1 vs 0).

Part A is the 12-week Randomized Placebo-Controlled Period (RCP), during which obexelimab or placebo will be administered as weekly subcutaneous (SC) injections. Following Part A, all patients will enter the Part B, a 12-week Open-Label Period (OLP), during which all patients will receive obexelimab administered as weekly SC injections. After Part B, patients will enter Part C, a 52-week Open-Label Extension (OLE), after which they will return for an in-clinic Safety Follow-Up Visit 12 weeks after the completion of Part C (i.e. Week 88). If at this time, B cells have not returned to baseline or above the lower limit of normal (LLN), patients will be asked to return every 12 weeks until B cells return to baseline or above the LLN (at minimum). The maximum expected duration of the study is 92 weeks (Screening Period = 4 weeks, Parts A, B and C = 76 weeks, Follow-up Period = 12 weeks).

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing Multiple Sclerosis
  • RMS
  • MS
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of RMS (relapsing-remitting or secondary progressive with relapses) according to the 2017 revision of the McDonald diagnostic criteria
  2. An EDSS of ≤ 5.5 at the Screening Visit
  3. Must have documentation of:

    1. . at least 1 relapse within the previous year OR
    2. . ≥ 2 relapses within the past 2 years OR
    3. . ≥ 1 active Gd-enhancing brain lesion on an MRI scan within the past 6 months prior to screening
  4. Not of or willing to follow guidance

Exclusion criteria

Exclusion Criteria:

  1. Primary progressive MS or secondary progressive MS without relapses
  2. Meet criteria for neuromyelitis optica spectrum disorder
  3. Relapse in the 30 days prior to randomization
  4. ≥ 10 years disease duration from onset with patient's EDSS ≤ 2.0 (patient reported is adequate in absence of written medical record)
  5. Has > 20 Gd+ lesions on brain MRI at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Obexelimab

    Obexelimab will be administered as a subcutaneous injection for 76 weeks

    Drug: Obexelimab

  • Placebo comparator
    Placebo

    Placebo will be administered as a subcutaneous injection for 12 weeks

    Drug: Placebo

Interventions

  • Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Cumulative number of new GdE T1 hyperintense lesions

    Cumulative number of new GdE T1 hyperintense lesions as measured by brain MRI

    Time frame: Week 8 and Week 12

Secondary outcomes

  1. Number of T2 Lesions

    cumulative number of new and/or enlarging T2 weighted hyperintense lesions

    Time frame: Week 8 and Week 12

  2. Number of GdE T1 lesions

    number of new GdE T1 hyperintense lesions

    Time frame: Week 4, Week 8, and Week 12

  3. Volume of T2 lesions

    change from baseline in volume of T2 lesions

    Time frame: Week 12

  4. Serum NfL

    serum NfL

    Time frame: Week 12

  5. Incidence of Adverse Events, injection site reactions and hypersensitivity reactions

    Incidence of Adverse Events, injection site reactions and hypersensitivity reactions, serious adverse events, and adverse events of special interest, as defined by the CTCAE v5.0

    Time frame: 24 weeks

07

Study locations

47 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2025, 12 months.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 12 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartActual
Aug 26, 2024
Primary completionActual
Aug 28, 2025
CompletionEst.
Feb 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564311
Lead sponsor
Zenas BioPharma (USA), LLC
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Aug 26, 2024
Primary completion
Aug 28, 2025
Completion
Feb 2026 (estimated)
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obexelimab

Start the discussion